Drugs / PEN-866
PEN-866
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04890093 | Oct 2024 → Dec 2026 | Ewing sarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1/2 | NCT03221400 | Aug 2017 → Jan 2023 | anal squamous cell carcinoma, cervical squamous cell carcinoma, endometrium adenocarcinoma, gastric adenocarcinoma +5 | Tarveda Therapeutics | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEN-866 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04890093 ↗ |
| Known as | HDC SN-38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297475 ↗ |
| Known as | Locnartecan | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297475 ↗ |
| Known as | SDC-TRAP 0063 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297475 ↗ |
| Known as | STA 12-8666 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297475 ↗ |
| Action | Inhibit | “PEN-866 is a novel molecule consisting of SN-38 conjugated to a heat shock protein 90 (HSP90) inhibitor” NCT04890093 ↗ |
| Modality | Other / unclassified | “miniaturized conjugate” NCT03221400 ↗ |
| Route | Intravenous | “PEN-866 Sodium administered intravenously” NCT03221400 ↗ |